China’s leading Biopharma event concludes successfully with 400+ industry attendees

25 May, 2018

Organised by IBC Asia, the annual Biopharma Development & Production (BDP) Week took place on 16 – 17 May 2018 at Hilton Shanghai Hongqiao Hotel. With three co-located conferences namely the 7th Annual Cell Line Development and Engineering Asia, 8th Annual Biomanufacturing and 9th Annual Biosimilars Asia, the event saw a total of 400+ biopharma participants representing pharma, biotech, CMOs, CROs, research institutes, investors, technology and industry stakeholders.

Over the 2-day conferences, participants were able to find out more about the latest developments in the cell lines, biosimilars, biobetters, antibodies, vaccines and novel biologics markets, and were provided with an excellent platform to network with renowned speakers and high-level decision makers from the industry.

Exclusive case studies & panel discussions with expert speakers

This year, the programme featured an exciting line-up of 80+ speakers from global, regional and local companies: CDER FDA (U.S), Pfizer Inc, Sandoz Biopharmaceuticals, Hangzhou JUST Biotherapeutics Co. Ltd, WuXi Biologics, Innovent Biologics, Akeso Bio, Generon Beijing, BeiGene Co Ltd, Shanghai Henlius Biotech Co Ltd, Quacell Biotech, Celltrion R&D, Samsung Bioepis, TOT Biopharma, A*STAR, and many more.

The morning plenary on Day 1 shines the spotlight on recent digitalisation and regulatory developments in the biomanufacturing, biosimilars and cell line markets. Panelists from China’s leading biopharma companies shared their perspectives on what to expect and what could possibly be leveraged to create new value for businesses.

Held consecutively across both days, the three tracks on Cell Line Development, Biomanufacturing and Biosimilars showcased numerous case studies from leading industry stakeholders that highlights their best practices and experiences in successfully tackling critical issues facing the industry.

Connecting and building partnerships at the BDP exhibition

The exhibition showcased over 30 companies from Merck, Pall Life Sciences, Boehringer Ingelheim, Charles River, Irvine Scientific, JSR Corporation, Kerry, Samsung Biologics, Thermo Fisher Scientific, and many other established industry stakeholders. Participants had the opportunity to meet and network with sponsors and exhibitors to learn more about these companies’ technologies, products and services that could help advance capabilities in the industry.
With the constantly-changing landscape of the biopharma industry in China and globally, BDP Week is the must-attend event for industry professionals to catch the latest developments and updates first-hand from government and private stakeholders.

We look forward to seeing you next year at BDP Week 2019 (14 – 16 May)!

For enquiries on registration, please contact:
Miki Kong
register@ibcasia.com.sg
+65 6508 2401
www.ibc-asia.com/event/biopharma-development-production

發表迴響

你的電子郵件位址並不會被公開。 必要欄位標記為 *